Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, post on X about a paper that He and His collogues co-authored in Blood Journal:
“Grateful to Blood Journal, co-authors, and SWOG for making this down with Dexamethasone piece possible!
Dex 40mg weekly in MM induction:
- Not practical even for trial-enrolled patients
- Does not improve PFS vs dex
Twitter once I’m back from IMS24!”
Quoting Robert Z. Orlowski post on X:
“Myeloma Paper of the Day: Cool paper from Rahul Banerjee, MD, showing analysis of S0777 and S1211 SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS and OS.”
Title: Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.
Authors: Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski
Read the full article on Blood Journal.
Read more posts featuring Rahul Banerjee on OncoDaily.